Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have garnered significant attention recently, both in the media and in doctors’ offices. Originally developed as a treatment for type 2 diabetes, ...

BeOne Medicines and AbbVie’s Pharmacyclics have decided to voluntarily dismiss the patent lawsuit the Big Pharma firm brought against its competitor over their BTK inhibitors. The patent covers a ...

The first oral BTK blocker for chronic spontaneous urticaria, Rhapsido offers a more convenient treatment option for patients who still show symptoms after antihistamine treatment. The FDA has ...

Novartis has scored the FDA’s approval for a second BTK inhibitor that’s for a non-cancer indication, teeing off a potential competition with Sanofi down the line. The FDA has blessed Novartis’ ...

SEATTLE--(BUSINESS WIRE)--Kayothera, Inc. (“Kayothera”), a preclinical therapeutics company developing first-in-class, small molecule inhibitors of the retinoid nuclear receptor pathway, today ...

Clinical Benefit From Molecularly Guided Cancer Care: A Matching-Adjusted Indirect Comparison of Larotrectinib Versus Standard of Care Four of 35 (11%; 95% CI, 3.2 to 26.7) HRP and four of 12 HRRm ...

Angiotensin converting enzyme (ACE) inhibitors, a type of blood pressure medication, are usually well tolerated, but one of their rare side effects is angioedema. Angiotensin converting enzyme (ACE) ...

A meta-analysis showed no significant differences between JAK inhibitor use and TNF antagonist use in terms of the risk for serious infections or malignant neoplasms in patients with immune-mediated ...

Serotonin reuptake inhibitors (SRIs) are a class of drugs that affect the brain’s serotonin system, and doctors most commonly prescribe them as antidepressants. SRIs increase the levels of serotonin ...

The PCSK9 inhibitor evolocumab (Repatha) got the FDA's blessing for cardiovascular protection, with or without a history of cardiovascular disease (CVD). Evolocumab is now indicated for the wider pool ...